ID   NED4L_HUMAN             Reviewed;         975 AA.
AC   Q96PU5; O43165; Q3LSM7; Q7Z5F1; Q7Z5F2; Q7Z5N3; Q8N5A7; Q8WUU9;
AC   Q9BW58; Q9H2W4; Q9NT88;
DT   30-AUG-2005, integrated into UniProtKB/Swiss-Prot.
DT   30-AUG-2005, sequence version 2.
DT   10-MAY-2017, entry version 158.
DE   RecName: Full=E3 ubiquitin-protein ligase NEDD4-like;
DE            EC=2.3.2.26;
DE   AltName: Full=HECT-type E3 ubiquitin transferase NED4L;
DE   AltName: Full=NEDD4.2;
DE   AltName: Full=Nedd4-2;
GN   Name=NEDD4L; Synonyms=KIAA0439, NEDL3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), AND ALTERNATIVE SPLICING.
RX   PubMed=11840194; DOI=10.1038/sj.ejhg.5200747;
RA   Chen H., Ross C.A., Wang N., Huo Y., MacKinnon D.F., Potash J.B.,
RA   Simpson S.G., McMahon F.J., DePaulo J.R. Jr., McInnis M.G.;
RT   "NEDD4L on human chromosome 18q21 has multiple forms of transcripts
RT   and is a homologue of the mouse Nedd4-2 gene.";
RL   Eur. J. Hum. Genet. 9:922-930(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH SCNN1A;
RP   SCNN1B AND SCNN1G.
RC   TISSUE=Kidney;
RX   PubMed=14556380; DOI=10.1016/S1631-0691(03)00154-9;
RA   Malbert-Colas L., Nicolas G., Galand C., Lecomte M.-C., Dhermy D.;
RT   "Identification of new partners of the epithelial sodium channel alpha
RT   subunit.";
RL   C. R. Biol. 326:615-624(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 4; 6 AND 7), TISSUE SPECIFICITY,
RP   AND INDUCTION.
RC   TISSUE=Prostate;
RX   PubMed=14615060; DOI=10.1016/j.mce.2003.08.009;
RA   Qi H., Grenier J., Fournier A., Labrie C.;
RT   "Androgens differentially regulate the expression of NEDD4L
RT   transcripts in LNCaP human prostate cancer cells.";
RL   Mol. Cell. Endocrinol. 210:51-62(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5).
RA   Okamoto Y., Miyazaki K., Sakamoto M., Kato C., Nakagawara A.;
RT   "Homo sapiens NEDD4-like ubiquitin ligase 3.";
RL   Submitted (SEP-2001) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 8).
RA   Qi H., Labrie C.;
RT   "NEDD4L transcripts expressed in human prostate cells.";
RL   Submitted (AUG-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16177791; DOI=10.1038/nature03983;
RA   Nusbaum C., Zody M.C., Borowsky M.L., Kamal M., Kodira C.D.,
RA   Taylor T.D., Whittaker C.A., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Yang X., Abouelleil A., Allen N.R., Anderson S.,
RA   Bloom T., Bugalter B., Butler J., Cook A., DeCaprio D., Engels R.,
RA   Garber M., Gnirke A., Hafez N., Hall J.L., Norman C.H., Itoh T.,
RA   Jaffe D.B., Kuroki Y., Lehoczky J., Lui A., Macdonald P., Mauceli E.,
RA   Mikkelsen T.S., Naylor J.W., Nicol R., Nguyen C., Noguchi H.,
RA   O'Leary S.B., Piqani B., Smith C.L., Talamas J.A., Topham K.,
RA   Totoki Y., Toyoda A., Wain H.M., Young S.K., Zeng Q., Zimmer A.R.,
RA   Fujiyama A., Hattori M., Birren B.W., Sakaki Y., Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 18.";
RL   Nature 437:551-555(2005).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] OF 101-975 (ISOFORM 5).
RC   TISSUE=Skin, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 8).
RC   TISSUE=Brain;
RX   PubMed=9455477; DOI=10.1093/dnares/4.5.307;
RA   Ishikawa K., Nagase T., Nakajima D., Seki N., Ohira M., Miyajima N.,
RA   Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. VIII.
RT   78 new cDNA clones from brain which code for large proteins in
RT   vitro.";
RL   DNA Res. 4:307-313(1997).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 52-975 (ISOFORM 3).
RC   TISSUE=Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [11]
RP   PROTEIN SEQUENCE OF 448-462, INTERACTION WITH YWHAB; YWHAG; YWHAE;
RP   YWHAQ AND YWHAH, PHOSPHORYLATION AT SER-448, MUTAGENESIS OF SER-448,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=15677482; DOI=10.1074/jbc.M412884200;
RA   Ichimura T., Yamamura H., Sasamoto K., Tominaga Y., Taoka M.,
RA   Kakiuchi K., Shinkawa T., Takahashi N., Shimada S., Isobe T.;
RT   "14-3-3 proteins modulate the expression of epithelial Na+ channels by
RT   phosphorylation-dependent interaction with Nedd4-2 ubiquitin ligase.";
RL   J. Biol. Chem. 280:13187-13194(2005).
RN   [12]
RP   INTERACTION WITH EPSTEIN-BARR VIRUS LMP2A.
RX   PubMed=11046148; DOI=10.1128/MCB.20.22.8526-8535.2000;
RA   Winberg G., Matskova L., Chen F., Plant P., Rotin D., Gish G.,
RA   Ingham R., Ernberg I., Pawson T.;
RT   "Latent membrane protein 2A of Epstein-Barr virus binds WW domain E3
RT   protein-ubiquitin ligases that ubiquitinate B-cell tyrosine kinases.";
RL   Mol. Cell. Biol. 20:8526-8535(2000).
RN   [13]
RP   INTERACTION WITH SGK1 AND SCNN1A, AND PHOSPHORYLATION.
RX   PubMed=11696533; DOI=10.1074/jbc.C100623200;
RA   Snyder P.M., Olson D.R., Thomas B.C.;
RT   "Serum and glucocorticoid-regulated kinase modulates Nedd4-2-mediated
RT   inhibition of the epithelial Na+ channel.";
RL   J. Biol. Chem. 277:5-8(2002).
RN   [14]
RP   INTERACTION WITH NDFIP1.
RX   PubMed=11748237; DOI=10.1074/jbc.M110443200;
RA   Harvey K.F., Shearwin-Whyatt L.M., Fotia A., Parton R.G., Kumar S.;
RT   "N4WBP5, a potential target for ubiquitination by the Nedd4 family of
RT   proteins, is a novel Golgi-associated protein.";
RL   J. Biol. Chem. 277:9307-9317(2002).
RN   [15]
RP   FUNCTION.
RX   PubMed=12911626;
RA   Boehmer C., Henke G., Schniepp R., Palmada M., Rothstein J.D.,
RA   Broeer S., Lang F.;
RT   "Regulation of the glutamate transporter EAAT1 by the ubiquitin ligase
RT   Nedd4-2 and the serum and glucocorticoid-inducible kinase isoforms
RT   SGK1/3 and protein kinase B.";
RL   J. Neurochem. 86:1181-1188(2003).
RN   [16]
RP   FUNCTION, MUTAGENESIS OF CYS-942, AND INTERACTION WITH SCN5A.
RX   PubMed=15217910; DOI=10.1161/01.RES.0000136816.05109.89;
RA   van Bemmelen M.X., Rougier J.-S., Gavillet B., Apotheloz F.,
RA   Daidie D., Tateyama M., Rivolta I., Thomas M.A., Kass R.S., Staub O.,
RA   Abriel H.;
RT   "Cardiac voltage-gated sodium channel Nav1.5 is regulated by Nedd4-2
RT   mediated ubiquitination.";
RL   Circ. Res. 95:284-291(2004).
RN   [17]
RP   FUNCTION, INTERACTION WITH CLCN5, AND INDUCTION.
RX   PubMed=15489223; DOI=10.1074/jbc.M411491200;
RA   Hryciw D.H., Ekberg J., Lee A., Lensink I.L., Kumar S., Guggino W.B.,
RA   Cook D.I., Pollock C.A., Poronnik P.;
RT   "Nedd4-2 functionally interacts with ClC-5: involvement in
RT   constitutive albumin endocytosis in proximal tubule cells.";
RL   J. Biol. Chem. 279:54996-55007(2004).
RN   [18]
RP   PHOSPHORYLATION AT SER-342; THR-367 AND SER-448.
RX   PubMed=15328345; DOI=10.1074/jbc.M407858200;
RA   Snyder P.M., Olson D.R., Kabra R., Zhou R., Steines J.C.;
RT   "cAMP and serum and glucocorticoid-inducible kinase (SGK) regulate the
RT   epithelial Na(+) channel through convergent phosphorylation of Nedd4-
RT   2.";
RL   J. Biol. Chem. 279:45753-45758(2004).
RN   [19]
RP   FUNCTION.
RX   PubMed=15040001; DOI=10.1002/jcp.10430;
RA   Henke G., Maier G., Wallisch S., Boehmer C., Lang F.;
RT   "Regulation of the voltage gated K+ channel Kv1.3 by the ubiquitin
RT   ligase Nedd4-2 and the serum and glucocorticoid inducible kinase
RT   SGK1.";
RL   J. Cell. Physiol. 199:194-199(2004).
RN   [20]
RP   INTERACTION WITH SCN2A; SCN3A AND SCN5A.
RX   PubMed=15548568; DOI=10.1152/ajpcell.00460.2004;
RA   Rougier J.-S., van Bemmelen M.X., Bruce M.C., Jespersen T.,
RA   Gavillet B., Apotheloz F., Cordonier S., Staub O., Rotin D.,
RA   Abriel H.;
RT   "Molecular determinants of voltage-gated sodium channel regulation by
RT   the Nedd4/Nedd4-like proteins.";
RL   Am. J. Physiol. 288:C692-C701(2005).
RN   [21]
RP   FUNCTION, INTERACTION WITH SMAD2; SMAD3; SMAD6 AND SMAD7, SUBCELLULAR
RP   LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=15496141; DOI=10.1042/BJ20040738;
RA   Kuratomi G., Komuro A., Goto K., Shinozaki M., Miyazawa K.,
RA   Miyazono K., Imamura T.;
RT   "NEDD4-2 (neural precursor cell expressed, developmentally down-
RT   regulated 4-2) negatively regulates TGF-beta (transforming growth
RT   factor-beta) signalling by inducing ubiquitin-mediated degradation of
RT   Smad2 and TGF-beta type I receptor.";
RL   Biochem. J. 386:461-470(2005).
RN   [22]
RP   FUNCTION.
RX   PubMed=15576372; DOI=10.1074/jbc.M411053200;
RA   Zhou R., Snyder P.M.;
RT   "Nedd4-2 phosphorylation induces serum and glucocorticoid-regulated
RT   kinase (SGK) ubiquitination and degradation.";
RL   J. Biol. Chem. 280:4518-4523(2005).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-479, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [24]
RP   SUBCELLULAR LOCATION.
RX   PubMed=18819914; DOI=10.1074/jbc.M804120200;
RA   Putz U., Howitt J., Lackovic J., Foot N., Kumar S., Silke J.,
RA   Tan S.S.;
RT   "Nedd4 family-interacting protein 1 (Ndfip1) is required for the
RT   exosomal secretion of Nedd4 family proteins.";
RL   J. Biol. Chem. 283:32621-32627(2008).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-318; SER-342; SER-446;
RP   SER-449; SER-464; SER-479 AND SER-487, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [28]
RP   INTERACTION WITH NPC2, AND TISSUE SPECIFICITY.
RX   PubMed=19664597; DOI=10.1016/j.bbrc.2009.07.158;
RA   Araki N., Ishigami T., Ushio H., Minegishi S., Umemura M., Miyagi Y.,
RA   Aoki I., Morinaga H., Tamura K., Toya Y., Uchino K., Umemura S.;
RT   "Identification of NPC2 protein as interaction molecule with C2 domain
RT   of human Nedd4L.";
RL   Biochem. Biophys. Res. Commun. 388:290-296(2009).
RN   [29]
RP   ACTIVATION BY NDFIP1 AND NDFIP2, AND AUTOUBIQUITINATION.
RX   PubMed=19343052; DOI=10.1038/embor.2009.30;
RA   Mund T., Pelham H.R.;
RT   "Control of the activity of WW-HECT domain E3 ubiquitin ligases by
RT   NDFIP proteins.";
RL   EMBO Rep. 10:501-507(2009).
RN   [30]
RP   FUNCTION AS A UBIQUITIN-PROTEIN LIGASE FOR TNK2, AND INTERACTION WITH
RP   TNK2.
RX   PubMed=19144635; DOI=10.1074/jbc.M806877200;
RA   Chan W., Tian R., Lee Y.-F., Sit S.T., Lim L., Manser E.;
RT   "Down-regulation of active ACK1 is mediated by association with the E3
RT   ubiquitin ligase Nedd4-2.";
RL   J. Biol. Chem. 284:8185-8194(2009).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-446, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [32]
RP   PHOSPHORYLATION AT SER-342 AND SER-449, AND INTERACTION WITH WNK1.
RX   PubMed=20525693; DOI=10.1074/jbc.M110.103432;
RA   Heise C.J., Xu B.E., Deaton S.L., Cha S.K., Cheng C.J., Earnest S.,
RA   Sengupta S., Juang Y.C., Stippec S., Xu Y., Zhao Y., Huang C.L.,
RA   Cobb M.H.;
RT   "Serum and glucocorticoid-induced kinase (SGK) 1 and the epithelial
RT   sodium channel are regulated by multiple with no lysine (WNK) family
RT   members.";
RL   J. Biol. Chem. 285:25161-25167(2010).
RN   [33]
RP   INTERACTION WITH TNK2.
RX   PubMed=20086093; DOI=10.1128/MCB.00013-10;
RA   Lin Q., Wang J., Childress C., Sudol M., Carey D.J., Yang W.;
RT   "HECT E3 ubiquitin ligase Nedd4-1 ubiquitinates ACK and regulates
RT   epidermal growth factor (EGF)-induced degradation of EGF receptor and
RT   ACK.";
RL   Mol. Cell. Biol. 30:1541-1554(2010).
RN   [34]
RP   PHOSPHORYLATION BY SGK1, AND INTERACTION WITH SGK1.
RX   PubMed=20730100; DOI=10.1371/journal.pone.0012163;
RA   Wiemuth D., Lott J.S., Ly K., Ke Y., Teesdale-Spittle P., Snyder P.M.,
RA   McDonald F.J.;
RT   "Interaction of serum- and glucocorticoid regulated kinase 1 (SGK1)
RT   with the WW-domains of Nedd4-2 is required for epithelial sodium
RT   channel regulation.";
RL   PLoS ONE 5:E12163-E12163(2010).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-479 AND SER-483, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [36]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [37]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-479; SER-483 AND
RP   SER-487, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [38]
RP   INTERACTION WITH KCNQ1.
RX   PubMed=22024150; DOI=10.1016/j.hrthm.2011.10.026;
RA   Krzystanek K., Rasmussen H.B., Grunnet M., Staub O., Olesen S.P.,
RA   Abriel H., Jespersen T.;
RT   "Deubiquitylating enzyme USP2 counteracts Nedd4-2-mediated
RT   downregulation of KCNQ1 potassium channels.";
RL   Heart Rhythm 9:440-448(2012).
RN   [39]
RP   INTERACTION WITH ARRDC4.
RX   PubMed=23236378; DOI=10.1371/journal.pone.0050557;
RA   Shea F.F., Rowell J.L., Li Y., Chang T.H., Alvarez C.E.;
RT   "Mammalian alpha arrestins link activated seven transmembrane
RT   receptors to Nedd4 family e3 ubiquitin ligases and interact with beta
RT   arrestins.";
RL   PLoS ONE 7:E50557-E50557(2012).
RN   [40]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [41]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=23999003; DOI=10.1016/j.jdermsci.2013.07.010;
RA   Yoo J.C., Lim T.Y., Park J.S., Hah Y.S., Park N., Hong S.G.,
RA   Park J.Y., Yoon T.J.;
RT   "SYT14L, especially its C2 domain, is involved in regulating
RT   melanocyte differentiation.";
RL   J. Dermatol. Sci. 72:246-251(2013).
RN   [42]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-312; THR-318; SER-448;
RP   SER-475; SER-479 AND SER-483, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [43]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [44]
RP   FUNCTION, INTERACTION WITH NDFIP1 AND NDFIP2, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=26363003; DOI=10.1042/BJ20141282;
RA   Kang Y., Guo J., Yang T., Li W., Zhang S.;
RT   "Regulation of the human ether-a-go-go-related gene (hERG) potassium
RT   channel by Nedd4 family interacting proteins (Ndfips).";
RL   Biochem. J. 472:71-82(2015).
RN   [45]
RP   FUNCTION IN UBIQUITINATION OF BRAT1.
RX   PubMed=25631046; DOI=10.1074/jbc.M114.613687;
RA   Low L.H., Chow Y.L., Li Y., Goh C.P., Putz U., Silke J., Ouchi T.,
RA   Howitt J., Tan S.S.;
RT   "Nedd4 family interacting protein 1 (Ndfip1) is required for
RT   ubiquitination and nuclear trafficking of BRCA1-associated ATM
RT   activator 1 (BRAT1) during the DNA damage response.";
RL   J. Biol. Chem. 290:7141-7150(2015).
RN   [46]
RP   FUNCTION, SUBCELLULAR LOCATION, INVOLVEMENT IN PVNH7, VARIANTS PVNH7
RP   CYS-679; HIS-694; LYS-893 AND GLN-897, AND CHARACTERIZATION OF
RP   VARIANTS PVNH7 HIS-694; LYS-893 AND GLN-897.
RX   PubMed=27694961; DOI=10.1038/ng.3676;
RG   Deciphering Developmental Disorders study;
RA   Broix L., Jagline H., Ivanova L.E., Schmucker S., Drouot N.,
RA   Clayton-Smith J., Pagnamenta A.T., Metcalfe K.A., Isidor B.,
RA   Louvier U.W., Poduri A., Taylor J.C., Tilly P., Poirier K.,
RA   Saillour Y., Lebrun N., Stemmelen T., Rudolf G., Muraca G.,
RA   Saintpierre B., Elmorjani A., Moise M., Weirauch N.B., Guerrini R.,
RA   Boland A., Olaso R., Masson C., Tripathy R., Keays D., Beldjord C.,
RA   Nguyen L., Godin J., Kini U., Nischke P., Deleuze J.F.,
RA   Bahi-Buisson N., Sumara I., Hinckelmann M.V., Chelly J.;
RT   "Mutations in the HECT domain of NEDD4L lead to AKT-mTOR pathway
RT   deregulation and cause periventricular nodular heterotopia.";
RL   Nat. Genet. 48:1349-1358(2016).
RN   [47]
RP   VARIANTS LEU-355 AND ARG-497.
RX   PubMed=15140763; DOI=10.1152/ajprenal.00353.2003;
RA   Fouladkou F., Alikhani-Koopaei R., Vogt B., Flores S.Y.,
RA   Malbert-Colas L., Lecomte M.-C., Loffing J., Frey F.J., Frey B.M.,
RA   Staub O.;
RT   "A naturally occurring human Nedd4-2 variant displays impaired ENaC
RT   regulation in Xenopus laevis oocytes.";
RL   Am. J. Physiol. 287:F550-F561(2004).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase which accepts ubiquitin from
CC       an E2 ubiquitin-conjugating enzyme in the form of a thioester and
CC       then directly transfers the ubiquitin to targeted substrates.
CC       Inhibits TGF-beta signaling by triggering SMAD2 and TGFBR1
CC       ubiquitination and proteasome-dependent degradation. Promotes
CC       ubiquitination and internalization of various plasma membrane
CC       channels such as ENaC, Nav1.2, Nav1.3, Nav1.5, Nav1.7, Nav1.8,
CC       Kv1.3, KCNH2, EAAT1 or CLC5 (PubMed:26363003). Promotes
CC       ubiquitination and degradation of SGK1 and TNK2. Ubiquitinates
CC       BRAT1 and this ubiquitination is enhanced in the presence of
CC       NDFIP1 (PubMed:25631046). Plays a role in dendrite formation by
CC       melanocytes (PubMed:23999003). Involved in the regulation of TOR
CC       signaling (PubMed:27694961). {ECO:0000250|UniProtKB:Q8CFI0,
CC       ECO:0000269|PubMed:12911626, ECO:0000269|PubMed:15040001,
CC       ECO:0000269|PubMed:15217910, ECO:0000269|PubMed:15489223,
CC       ECO:0000269|PubMed:15496141, ECO:0000269|PubMed:15576372,
CC       ECO:0000269|PubMed:19144635, ECO:0000269|PubMed:23999003,
CC       ECO:0000269|PubMed:25631046, ECO:0000269|PubMed:26363003,
CC       ECO:0000269|PubMed:27694961}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine.
CC   -!- ENZYME REGULATION: Activated by NDFIP1- and NDFIP2-binding.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Interacts with UBE2E3 (By similarity). Interacts with
CC       NDFIP1 and NDFIP2; this interaction activates the E3 ubiquitin-
CC       protein ligase (PubMed:26363003, PubMed:11748237). Interacts via
CC       its WW domains with SCNN1A, SCNN1B, SCNN1G, SCN1A, SCN2A, SCN3A,
CC       SCN5A, SCN8A, SCN9A, SCN10A and CLCN5 (PubMed:11696533,
CC       PubMed:14556380, PubMed:15217910, PubMed:15489223,
CC       PubMed:15548568). Interacts with SMAD2, SMAD3, SMAD6 and SMAD7
CC       (PubMed:15496141). The phosphorylated form interacts with 14-3-3
CC       proteins (PubMed:15677482). Interacts with Epstein-Barr virus
CC       LMP2A (PubMed:11046148). Interacts with TNK2 (PubMed:19144635,
CC       PubMed:20086093). Interacts with WNK1 (PubMed:20525693). Interacts
CC       with SGK1 (PubMed:11696533, PubMed:20730100). Interacts (via C2
CC       domain) with NPC2 (PubMed:19664597). Interacts with ARRDC4
CC       (PubMed:23236378). Interacts with KCNQ1; promotes internalization
CC       of KCNQ1 (PubMed:22024150). {ECO:0000250|UniProtKB:Q8CFI0,
CC       ECO:0000269|PubMed:11046148, ECO:0000269|PubMed:11696533,
CC       ECO:0000269|PubMed:11748237, ECO:0000269|PubMed:14556380,
CC       ECO:0000269|PubMed:15217910, ECO:0000269|PubMed:15489223,
CC       ECO:0000269|PubMed:15496141, ECO:0000269|PubMed:15548568,
CC       ECO:0000269|PubMed:15677482, ECO:0000269|PubMed:19144635,
CC       ECO:0000269|PubMed:19664597, ECO:0000269|PubMed:20086093,
CC       ECO:0000269|PubMed:20525693, ECO:0000269|PubMed:20730100,
CC       ECO:0000269|PubMed:22024150, ECO:0000269|PubMed:23236378,
CC       ECO:0000269|PubMed:26363003}.
CC   -!- INTERACTION:
CC       Q15038:DAZAP2; NbExp=3; IntAct=EBI-717962, EBI-724310;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15496141,
CC       ECO:0000269|PubMed:18819914, ECO:0000269|PubMed:27694961}. Golgi
CC       apparatus {ECO:0000269|PubMed:26363003}. Endosome, multivesicular
CC       body {ECO:0000269|PubMed:26363003}. Note=May be recruited to
CC       exosomes by NDFIP1.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=8;
CC       Name=1; Synonyms=Nedd4-2c;
CC         IsoId=Q96PU5-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q96PU5-2; Sequence=VSP_015448;
CC         Note=No experimental confirmation available.;
CC       Name=3; Synonyms=NEDD4Le;
CC         IsoId=Q96PU5-3; Sequence=VSP_015447;
CC         Note=No experimental confirmation available.;
CC       Name=4; Synonyms=NEDD4La, NEDD4Lb, NEDD4Lf;
CC         IsoId=Q96PU5-4; Sequence=VSP_015444;
CC       Name=5; Synonyms=NEDD4Ld;
CC         IsoId=Q96PU5-5; Sequence=VSP_043848;
CC       Name=6; Synonyms=NEDD4Lh;
CC         IsoId=Q96PU5-6; Sequence=VSP_015446, VSP_043848;
CC       Name=7; Synonyms=NEDD4Lg;
CC         IsoId=Q96PU5-7; Sequence=VSP_015446;
CC       Name=8;
CC         IsoId=Q96PU5-9; Sequence=VSP_015444, VSP_043848;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed, with highest levels in
CC       prostate, pancreas and kidney (PubMed:14615060, PubMed:15496141,
CC       PubMed:19664597). Expressed in melanocytes (PubMed:23999003).
CC       {ECO:0000269|PubMed:14615060, ECO:0000269|PubMed:15496141,
CC       ECO:0000269|PubMed:19664597, ECO:0000269|PubMed:23999003}.
CC   -!- INDUCTION: By androgens in prostate, and by albumin in kidney.
CC       {ECO:0000269|PubMed:14615060, ECO:0000269|PubMed:15489223}.
CC   -!- PTM: Phosphorylated by SGK1 or PKA; which impairs interaction with
CC       SCNN. Interaction with YWHAH inhibits dephosphorylation.
CC       {ECO:0000269|PubMed:11696533, ECO:0000269|PubMed:15328345,
CC       ECO:0000269|PubMed:15677482, ECO:0000269|PubMed:20525693,
CC       ECO:0000269|PubMed:20730100}.
CC   -!- PTM: Auto-ubiquitinated. {ECO:0000269|PubMed:19343052}.
CC   -!- DISEASE: Periventricular nodular heterotopia 7 (PVNH7)
CC       [MIM:617201]: A form of periventricular nodular heterotopia, a
CC       disorder resulting from a defect in the pattern of neuronal
CC       migration in which ectopic collections of neurons lie along the
CC       lateral ventricles of the brain or just beneath, contiguously or
CC       in isolated patches. PVNH7 is an autosomal dominant disease
CC       characterized by delayed psychomotor development, intellectual
CC       disability, and seizures in some patients. Additional features
CC       include cleft palate and toe syndactyly.
CC       {ECO:0000269|PubMed:27694961}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA23711.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC       Sequence=BAA23711.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF210730; AAG43524.1; -; mRNA.
DR   EMBL; AF385931; AAM46208.1; -; mRNA.
DR   EMBL; AY312514; AAP75706.1; -; mRNA.
DR   EMBL; AY112983; AAM76728.1; -; mRNA.
DR   EMBL; AY112984; AAM76729.1; -; mRNA.
DR   EMBL; AY112985; AAM76730.1; -; mRNA.
DR   EMBL; AB071179; BAB69424.1; -; mRNA.
DR   EMBL; DQ181796; ABA10330.1; -; mRNA.
DR   EMBL; AC015988; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC090236; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC107896; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471096; EAW63065.1; -; Genomic_DNA.
DR   EMBL; BC000621; AAH00621.2; -; mRNA.
DR   EMBL; BC019345; AAH19345.1; -; mRNA.
DR   EMBL; BC032597; AAH32597.1; -; mRNA.
DR   EMBL; AB007899; BAA23711.1; ALT_INIT; mRNA.
DR   EMBL; AL137469; CAB70754.1; -; mRNA.
DR   CCDS; CCDS45872.1; -. [Q96PU5-1]
DR   CCDS; CCDS45873.1; -. [Q96PU5-5]
DR   CCDS; CCDS45874.1; -. [Q96PU5-7]
DR   CCDS; CCDS45875.1; -. [Q96PU5-4]
DR   CCDS; CCDS45876.1; -. [Q96PU5-9]
DR   CCDS; CCDS58632.1; -. [Q96PU5-2]
DR   CCDS; CCDS59323.1; -. [Q96PU5-6]
DR   PIR; T46412; T46412.
DR   RefSeq; NP_001138436.1; NM_001144964.1. [Q96PU5-4]
DR   RefSeq; NP_001138437.1; NM_001144965.1. [Q96PU5-4]
DR   RefSeq; NP_001138438.1; NM_001144966.2. [Q96PU5-4]
DR   RefSeq; NP_001138439.1; NM_001144967.2. [Q96PU5-1]
DR   RefSeq; NP_001138440.1; NM_001144968.1. [Q96PU5-7]
DR   RefSeq; NP_001138441.1; NM_001144969.1. [Q96PU5-6]
DR   RefSeq; NP_001138442.1; NM_001144970.2. [Q96PU5-9]
DR   RefSeq; NP_001138443.1; NM_001144971.1. [Q96PU5-9]
DR   RefSeq; NP_001230889.1; NM_001243960.1. [Q96PU5-2]
DR   RefSeq; NP_056092.2; NM_015277.5. [Q96PU5-5]
DR   RefSeq; XP_016881168.1; XM_017025679.1. [Q96PU5-4]
DR   UniGene; Hs.185677; -.
DR   PDB; 2LAJ; NMR; -; A=496-535.
DR   PDB; 2LB2; NMR; -; A=386-420.
DR   PDB; 2LTY; NMR; -; A=385-417.
DR   PDB; 2MPT; NMR; -; A=496-539, B=945-957.
DR   PDB; 2NSQ; X-ray; 1.85 A; A=1-154.
DR   PDB; 2ONI; X-ray; 2.20 A; A=594-967.
DR   PDB; 3JVZ; X-ray; 3.30 A; C/D=596-975.
DR   PDB; 3JW0; X-ray; 3.10 A; C/D=596-975.
DR   PDB; 5HPK; X-ray; 2.43 A; A=594-975.
DR   PDBsum; 2LAJ; -.
DR   PDBsum; 2LB2; -.
DR   PDBsum; 2LTY; -.
DR   PDBsum; 2MPT; -.
DR   PDBsum; 2NSQ; -.
DR   PDBsum; 2ONI; -.
DR   PDBsum; 3JVZ; -.
DR   PDBsum; 3JW0; -.
DR   PDBsum; 5HPK; -.
DR   ProteinModelPortal; Q96PU5; -.
DR   SMR; Q96PU5; -.
DR   BioGrid; 116915; 191.
DR   DIP; DIP-41935N; -.
DR   IntAct; Q96PU5; 25.
DR   MINT; MINT-148327; -.
DR   STRING; 9606.ENSP00000383199; -.
DR   iPTMnet; Q96PU5; -.
DR   PhosphoSitePlus; Q96PU5; -.
DR   BioMuta; NEDD4L; -.
DR   DMDM; 73921204; -.
DR   EPD; Q96PU5; -.
DR   MaxQB; Q96PU5; -.
DR   PaxDb; Q96PU5; -.
DR   PeptideAtlas; Q96PU5; -.
DR   PRIDE; Q96PU5; -.
DR   DNASU; 23327; -.
DR   Ensembl; ENST00000256830; ENSP00000256830; ENSG00000049759. [Q96PU5-3]
DR   Ensembl; ENST00000356462; ENSP00000348847; ENSG00000049759. [Q96PU5-2]
DR   Ensembl; ENST00000357895; ENSP00000350569; ENSG00000049759. [Q96PU5-7]
DR   Ensembl; ENST00000382850; ENSP00000372301; ENSG00000049759. [Q96PU5-5]
DR   Ensembl; ENST00000400345; ENSP00000383199; ENSG00000049759. [Q96PU5-1]
DR   Ensembl; ENST00000431212; ENSP00000389406; ENSG00000049759. [Q96PU5-4]
DR   Ensembl; ENST00000435432; ENSP00000393395; ENSG00000049759. [Q96PU5-9]
DR   Ensembl; ENST00000456173; ENSP00000405440; ENSG00000049759. [Q96PU5-9]
DR   Ensembl; ENST00000456986; ENSP00000411947; ENSG00000049759. [Q96PU5-4]
DR   Ensembl; ENST00000586263; ENSP00000468546; ENSG00000049759. [Q96PU5-6]
DR   GeneID; 23327; -.
DR   KEGG; hsa:23327; -.
DR   UCSC; uc002lgx.4; human. [Q96PU5-1]
DR   CTD; 23327; -.
DR   DisGeNET; 23327; -.
DR   GeneCards; NEDD4L; -.
DR   HGNC; HGNC:7728; NEDD4L.
DR   HPA; HPA024618; -.
DR   HPA; HPA064730; -.
DR   MIM; 606384; gene.
DR   MIM; 617201; phenotype.
DR   neXtProt; NX_Q96PU5; -.
DR   OpenTargets; ENSG00000049759; -.
DR   PharmGKB; PA31534; -.
DR   eggNOG; KOG0940; Eukaryota.
DR   eggNOG; COG5021; LUCA.
DR   GeneTree; ENSGT00760000118966; -.
DR   HOVERGEN; HBG004134; -.
DR   InParanoid; Q96PU5; -.
DR   KO; K13305; -.
DR   OMA; FDENRLX; -.
DR   OrthoDB; EOG091G0SS8; -.
DR   PhylomeDB; Q96PU5; -.
DR   TreeFam; TF323658; -.
DR   BRENDA; 2.3.2.B8; 2681.
DR   BRENDA; 6.3.2.19; 2681.
DR   Reactome; R-HSA-162588; Budding and maturation of HIV virion.
DR   Reactome; R-HSA-2173788; Downregulation of TGF-beta receptor signaling.
DR   Reactome; R-HSA-2173795; Downregulation of SMAD2/3:SMAD4 transcriptional activity.
DR   Reactome; R-HSA-2672351; Stimuli-sensing channels.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   SignaLink; Q96PU5; -.
DR   SIGNOR; Q96PU5; -.
DR   UniPathway; UPA00143; -.
DR   ChiTaRS; NEDD4L; human.
DR   EvolutionaryTrace; Q96PU5; -.
DR   GeneWiki; NEDD4L; -.
DR   GenomeRNAi; 23327; -.
DR   PRO; PR:Q96PU5; -.
DR   Proteomes; UP000005640; Chromosome 18.
DR   Bgee; ENSG00000049759; -.
DR   ExpressionAtlas; Q96PU5; baseline and differential.
DR   Genevisible; Q96PU5; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005622; C:intracellular; IC:UniProtKB.
DR   GO; GO:0005771; C:multivesicular body; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0044325; F:ion channel binding; IPI:BHF-UCL.
DR   GO; GO:0019870; F:potassium channel inhibitor activity; IDA:BHF-UCL.
DR   GO; GO:0015459; F:potassium channel regulator activity; IDA:BHF-UCL.
DR   GO; GO:0019871; F:sodium channel inhibitor activity; IDA:BHF-UCL.
DR   GO; GO:0017080; F:sodium channel regulator activity; IDA:UniProtKB.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; EXP:Reactome.
DR   GO; GO:0006883; P:cellular sodium ion homeostasis; NAS:UniProtKB.
DR   GO; GO:0007588; P:excretion; NAS:UniProtKB.
DR   GO; GO:0034220; P:ion transmembrane transport; TAS:Reactome.
DR   GO; GO:1901380; P:negative regulation of potassium ion transmembrane transport; IDA:BHF-UCL.
DR   GO; GO:1901017; P:negative regulation of potassium ion transmembrane transporter activity; IDA:BHF-UCL.
DR   GO; GO:2000009; P:negative regulation of protein localization to cell surface; IDA:BHF-UCL.
DR   GO; GO:1902306; P:negative regulation of sodium ion transmembrane transport; IDA:BHF-UCL.
DR   GO; GO:2000650; P:negative regulation of sodium ion transmembrane transporter activity; IDA:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; TAS:Reactome.
DR   GO; GO:2001288; P:positive regulation of caveolin-mediated endocytosis; ISS:BHF-UCL.
DR   GO; GO:1903861; P:positive regulation of dendrite extension; IDA:UniProtKB.
DR   GO; GO:0045807; P:positive regulation of endocytosis; NAS:UniProtKB.
DR   GO; GO:0045732; P:positive regulation of protein catabolic process; IEA:Ensembl.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IDA:BHF-UCL.
DR   GO; GO:0070936; P:protein K48-linked ubiquitination; IDA:BHF-UCL.
DR   GO; GO:0006513; P:protein monoubiquitination; IEA:Ensembl.
DR   GO; GO:0000209; P:protein polyubiquitination; TAS:Reactome.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0042787; P:protein ubiquitination involved in ubiquitin-dependent protein catabolic process; IDA:BHF-UCL.
DR   GO; GO:0034765; P:regulation of ion transmembrane transport; IDA:BHF-UCL.
DR   GO; GO:0003254; P:regulation of membrane depolarization; IDA:BHF-UCL.
DR   GO; GO:0042391; P:regulation of membrane potential; IDA:BHF-UCL.
DR   GO; GO:0060306; P:regulation of membrane repolarization; IDA:BHF-UCL.
DR   GO; GO:1901016; P:regulation of potassium ion transmembrane transporter activity; IDA:BHF-UCL.
DR   GO; GO:0042176; P:regulation of protein catabolic process; NAS:UniProtKB.
DR   GO; GO:0010038; P:response to metal ion; IDA:UniProtKB.
DR   GO; GO:0006814; P:sodium ion transport; NAS:UniProtKB.
DR   GO; GO:0086005; P:ventricular cardiac muscle cell action potential; ISS:BHF-UCL.
DR   GO; GO:0019058; P:viral life cycle; TAS:Reactome.
DR   GO; GO:0030104; P:water homeostasis; NAS:UniProtKB.
DR   CDD; cd00078; HECTc; 1.
DR   Gene3D; 2.60.40.150; -; 1.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR000569; HECT_dom.
DR   InterPro; IPR001202; WW_dom.
DR   Pfam; PF00168; C2; 1.
DR   Pfam; PF00632; HECT; 1.
DR   Pfam; PF00397; WW; 4.
DR   PRINTS; PR00360; C2DOMAIN.
DR   SMART; SM00239; C2; 1.
DR   SMART; SM00119; HECTc; 1.
DR   SMART; SM00456; WW; 4.
DR   SUPFAM; SSF49562; SSF49562; 1.
DR   SUPFAM; SSF51045; SSF51045; 4.
DR   SUPFAM; SSF56204; SSF56204; 1.
DR   PROSITE; PS50004; C2; 1.
DR   PROSITE; PS50237; HECT; 1.
DR   PROSITE; PS01159; WW_DOMAIN_1; 4.
DR   PROSITE; PS50020; WW_DOMAIN_2; 4.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Complete proteome;
KW   Cytoplasm; Differentiation; Direct protein sequencing; Endosome;
KW   Golgi apparatus; Host-virus interaction; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Transferase; Ubl conjugation;
KW   Ubl conjugation pathway.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:22814378}.
FT   CHAIN         2    975       E3 ubiquitin-protein ligase NEDD4-like.
FT                                /FTId=PRO_0000120323.
FT   DOMAIN        7    109       C2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00041}.
FT   DOMAIN      193    226       WW 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00224}.
FT   DOMAIN      385    418       WW 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00224}.
FT   DOMAIN      497    530       WW 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00224}.
FT   DOMAIN      548    581       WW 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00224}.
FT   DOMAIN      640    974       HECT. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00104}.
FT   ACT_SITE    942    942       Glycyl thioester intermediate.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:22814378}.
FT   MOD_RES     312    312       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     318    318       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     342    342       Phosphoserine; by WNK1 and WNK4.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000269|PubMed:15328345,
FT                                ECO:0000269|PubMed:20525693}.
FT   MOD_RES     367    367       Phosphothreonine; by SGK1.
FT                                {ECO:0000305|PubMed:15328345}.
FT   MOD_RES     446    446       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332}.
FT   MOD_RES     448    448       Phosphoserine; by PKA and SGK1.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:15328345,
FT                                ECO:0000269|PubMed:15677482}.
FT   MOD_RES     449    449       Phosphoserine; by WNK1 and WNK4.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000269|PubMed:20525693}.
FT   MOD_RES     464    464       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     475    475       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     479    479       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     483    483       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     487    487       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:21406692}.
FT   VAR_SEQ       1    121       Missing (in isoform 4 and isoform 8).
FT                                {ECO:0000303|PubMed:11840194,
FT                                ECO:0000303|PubMed:14615060,
FT                                ECO:0000303|PubMed:9455477,
FT                                ECO:0000303|Ref.5}.
FT                                /FTId=VSP_015444.
FT   VAR_SEQ       1     16       MATGLGEPVYGLSEDE -> MRRLAFEQ (in isoform
FT                                6 and isoform 7).
FT                                {ECO:0000303|PubMed:14615060}.
FT                                /FTId=VSP_015446.
FT   VAR_SEQ     356    459       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:17974005}.
FT                                /FTId=VSP_015447.
FT   VAR_SEQ     356    419       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_015448.
FT   VAR_SEQ     356    375       Missing (in isoform 5, isoform 6 and
FT                                isoform 8). {ECO:0000303|PubMed:14615060,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:9455477,
FT                                ECO:0000303|Ref.4, ECO:0000303|Ref.5}.
FT                                /FTId=VSP_043848.
FT   VARIANT     355    355       P -> L (common polymorphism; impaired
FT                                ability to inhibit SCNN;
FT                                dbSNP:rs767136811).
FT                                {ECO:0000269|PubMed:15140763}.
FT                                /FTId=VAR_023415.
FT   VARIANT     497    497       S -> R. {ECO:0000269|PubMed:15140763}.
FT                                /FTId=VAR_023416.
FT   VARIANT     679    679       Y -> C (in PVNH7).
FT                                {ECO:0000269|PubMed:27694961}.
FT                                /FTId=VAR_077880.
FT   VARIANT     694    694       Q -> H (in PVNH7; increased degradation;
FT                                changed function in regulation of TOR
FT                                signaling).
FT                                {ECO:0000269|PubMed:27694961}.
FT                                /FTId=VAR_077881.
FT   VARIANT     893    893       E -> K (in PVNH7; increased degradation;
FT                                changed function in regulation of TOR
FT                                signaling).
FT                                {ECO:0000269|PubMed:27694961}.
FT                                /FTId=VAR_077882.
FT   VARIANT     897    897       R -> Q (in PVNH7; increased degradation;
FT                                changed function in regulation of TOR
FT                                signaling).
FT                                {ECO:0000269|PubMed:27694961}.
FT                                /FTId=VAR_077883.
FT   MUTAGEN     448    448       S->A: Abolishes interaction with 1433F.
FT                                {ECO:0000269|PubMed:15677482}.
FT   MUTAGEN     942    942       C->S: Abolishes activity.
FT                                {ECO:0000269|PubMed:15217910}.
FT   CONFLICT     52     52       A -> P (in Ref. 3; AAM76729/AAM76730).
FT                                {ECO:0000305}.
FT   CONFLICT    188    188       E -> K (in Ref. 2; AAP75706).
FT                                {ECO:0000305}.
FT   STRAND        9     11       {ECO:0000244|PDB:2NSQ}.
FT   TURN         16     18       {ECO:0000244|PDB:2NSQ}.
FT   STRAND       20     31       {ECO:0000244|PDB:2NSQ}.
FT   STRAND       43     51       {ECO:0000244|PDB:2NSQ}.
FT   TURN         52     55       {ECO:0000244|PDB:2NSQ}.
FT   STRAND       56     62       {ECO:0000244|PDB:2NSQ}.
FT   STRAND       73     82       {ECO:0000244|PDB:2NSQ}.
FT   TURN         84     86       {ECO:0000244|PDB:2NSQ}.
FT   STRAND       87     95       {ECO:0000244|PDB:2NSQ}.
FT   STRAND       98    100       {ECO:0000244|PDB:2NSQ}.
FT   STRAND      103    111       {ECO:0000244|PDB:2NSQ}.
FT   STRAND      129    132       {ECO:0000244|PDB:2NSQ}.
FT   STRAND      145    152       {ECO:0000244|PDB:2NSQ}.
FT   STRAND      391    396       {ECO:0000244|PDB:2LB2}.
FT   TURN        397    399       {ECO:0000244|PDB:2LB2}.
FT   STRAND      400    405       {ECO:0000244|PDB:2LB2}.
FT   TURN        406    409       {ECO:0000244|PDB:2LB2}.
FT   STRAND      410    414       {ECO:0000244|PDB:2LB2}.
FT   HELIX       417    419       {ECO:0000244|PDB:2LB2}.
FT   STRAND      503    508       {ECO:0000244|PDB:2LAJ}.
FT   TURN        509    511       {ECO:0000244|PDB:2LAJ}.
FT   STRAND      512    517       {ECO:0000244|PDB:2LAJ}.
FT   TURN        518    521       {ECO:0000244|PDB:2LAJ}.
FT   STRAND      522    526       {ECO:0000244|PDB:2LAJ}.
FT   HELIX       528    534       {ECO:0000244|PDB:2LAJ}.
FT   HELIX       594    607       {ECO:0000244|PDB:2ONI}.
FT   STRAND      612    614       {ECO:0000244|PDB:2ONI}.
FT   STRAND      616    622       {ECO:0000244|PDB:2ONI}.
FT   HELIX       624    626       {ECO:0000244|PDB:2ONI}.
FT   HELIX       627    637       {ECO:0000244|PDB:2ONI}.
FT   HELIX       641    645       {ECO:0000244|PDB:2ONI}.
FT   STRAND      646    652       {ECO:0000244|PDB:2ONI}.
FT   STRAND      653    655       {ECO:0000244|PDB:3JVZ}.
FT   HELIX       660    675       {ECO:0000244|PDB:2ONI}.
FT   HELIX       678    680       {ECO:0000244|PDB:2ONI}.
FT   STRAND      681    687       {ECO:0000244|PDB:2ONI}.
FT   TURN        688    690       {ECO:0000244|PDB:3JW0}.
FT   STRAND      693    695       {ECO:0000244|PDB:2ONI}.
FT   HELIX       699    702       {ECO:0000244|PDB:2ONI}.
FT   HELIX       706    723       {ECO:0000244|PDB:2ONI}.
FT   STRAND      728    731       {ECO:0000244|PDB:3JW0}.
FT   HELIX       733    739       {ECO:0000244|PDB:2ONI}.
FT   HELIX       746    749       {ECO:0000244|PDB:2ONI}.
FT   TURN        750    752       {ECO:0000244|PDB:2ONI}.
FT   HELIX       754    765       {ECO:0000244|PDB:2ONI}.
FT   HELIX       769    771       {ECO:0000244|PDB:2ONI}.
FT   STRAND      774    781       {ECO:0000244|PDB:2ONI}.
FT   STRAND      784    791       {ECO:0000244|PDB:2ONI}.
FT   HELIX       794    796       {ECO:0000244|PDB:2ONI}.
FT   TURN        801    803       {ECO:0000244|PDB:2ONI}.
FT   HELIX       804    816       {ECO:0000244|PDB:2ONI}.
FT   TURN        817    819       {ECO:0000244|PDB:2ONI}.
FT   HELIX       821    834       {ECO:0000244|PDB:2ONI}.
FT   HELIX       837    840       {ECO:0000244|PDB:2ONI}.
FT   HELIX       845    853       {ECO:0000244|PDB:2ONI}.
FT   HELIX       860    865       {ECO:0000244|PDB:2ONI}.
FT   STRAND      868    870       {ECO:0000244|PDB:2ONI}.
FT   HELIX       878    889       {ECO:0000244|PDB:2ONI}.
FT   HELIX       892    903       {ECO:0000244|PDB:2ONI}.
FT   HELIX       913    915       {ECO:0000244|PDB:2ONI}.
FT   STRAND      919    922       {ECO:0000244|PDB:5HPK}.
FT   STRAND      926    929       {ECO:0000244|PDB:2ONI}.
FT   STRAND      933    935       {ECO:0000244|PDB:3JW0}.
FT   STRAND      938    940       {ECO:0000244|PDB:2ONI}.
FT   HELIX       941    943       {ECO:0000244|PDB:2ONI}.
FT   STRAND      945    948       {ECO:0000244|PDB:2ONI}.
FT   HELIX       954    965       {ECO:0000244|PDB:2ONI}.
SQ   SEQUENCE   975 AA;  111932 MW;  2C958625B4A1AB3F CRC64;
     MATGLGEPVY GLSEDEGESR ILRVKVVSGI DLAKKDIFGA SDPYVKLSLY VADENRELAL
     VQTKTIKKTL NPKWNEEFYF RVNPSNHRLL FEVFDENRLT RDDFLGQVDV PLSHLPTEDP
     TMERPYTFKD FLLRPRSHKS RVKGFLRLKM AYMPKNGGQD EENSDQRDDM EHGWEVVDSN
     DSASQHQEEL PPPPLPPGWE EKVDNLGRTY YVNHNNRTTQ WHRPSLMDVS SESDNNIRQI
     NQEAAHRRFR SRRHISEDLE PEPSEGGDVP EPWETISEEV NIAGDSLGLA LPPPPASPGS
     RTSPQELSEE LSRRLQITPD SNGEQFSSLI QREPSSRLRS CSVTDAVAEQ GHLPPPSAPA
     GRARSSTVTG GEEPTPSVAY VHTTPGLPSG WEERKDAKGR TYYVNHNNRT TTWTRPIMQL
     AEDGASGSAT NSNNHLIEPQ IRRPRSLSSP TVTLSAPLEG AKDSPVRRAV KDTLSNPQSP
     QPSPYNSPKP QHKVTQSFLP PGWEMRIAPN GRPFFIDHNT KTTTWEDPRL KFPVHMRSKT
     SLNPNDLGPL PPGWEERIHL DGRTFYIDHN SKITQWEDPR LQNPAITGPA VPYSREFKQK
     YDYFRKKLKK PADIPNRFEM KLHRNNIFEE SYRRIMSVKR PDVLKARLWI EFESEKGLDY
     GGVAREWFFL LSKEMFNPYY GLFEYSATDN YTLQINPNSG LCNEDHLSYF TFIGRVAGLA
     VFHGKLLDGF FIRPFYKMML GKQITLNDME SVDSEYYNSL KWILENDPTE LDLMFCIDEE
     NFGQTYQVDL KPNGSEIMVT NENKREYIDL VIQWRFVNRV QKQMNAFLEG FTELLPIDLI
     KIFDENELEL LMCGLGDVDV NDWRQHSIYK NGYCPNHPVI QWFWKAVLLM DAEKRIRLLQ
     FVTGTSRVPM NGFAELYGSN GPQLFTIEQW GSPEKLPRAH TCFNRLDLPP YETFEDLREK
     LLMAVENAQG FEGVD
//
